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were 7.64% for GLAR and 7.87% for DET at the follow-up
visit. After adjusting for baseline characteristics and HbA1c and
concomitant antidiabetic medications during the follow-up
period, A1C remained lower in GLAR versus DET (7.06 vs
7.84%, P = 0.0178). Total insulin dose in GLAR was increased
from 45.3 U to 75.8 U at the follow-up visit and 33.5 U to
48.6 U in DET. Adjusted weight was 101.2 kg for GLAR and
97.1 kg for DET. CONCLUSIONS: Initiation of GLAR relative
to DET in T2D patients is associated with greater improvement
in glycemic control achieved within six months. More exenatide
use in DET relative to GLAR may possibly explain the group
difference in body weight. This analysis was conducted in a single
clinical practice hence further studies are needed to determine
reproducibility of the ﬁndings.
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OBJECTIVES: A meta-analysis of Pioglitazone and Rosiglita-
zone in patients with type 2 diabetes was conducted to evaluate
the effects of each drug on glycemic control, lipids, blood pres-
sure, and weight. In addition, this study was aimed to identify if
there is an ethnic difference in the effects between Asian and
Caucasian patients by subgroup analysis. METHODS: Among
the randomized controlled trials of Pioglitazone or Rosiglitazone
which had been published before February 2008, 63 randomized
controlled trials that were eligible for the inclusion/exclusion
criteria were collected. For quantitative meta-analysis, the
weighted pooled effect sizes and their 95% conﬁdence intervals
were calculated. RESULTS: Glucose lowering effect was higher
in Rosiglitazone, whereas Pioglitazone produced a more favor-
able lipid proﬁle. Both thiazolidinediones demonstrated similar
increases in body weight. The effect on blood pressure was
slightly higher in Pioglitazone. Regarding the effects of Pioglita-
zone, the pooled effect sizes of Pioglitazone 15 mg were very
similar for two different ethnic groups in all parameters. When
the effects of Pioglitazone in Caucasian patients group at dose of
30 mg and Asian patients group at dose of 15 mg were com-
pared, most of the overall effects sizes were higher in Caucasian
patients group than that of Asian patients group. In case of
Rosiglitazone, the pooled effect sizes of Asian patients group
administered 4 mg were higher than Caucasian patients group
administered the same dose. Furthermore, in comparing the
effect sizes of Asian patients group administered 4 mg and Cau-
casian patients group administered 8 mg, the effect sizes were
rather similar than they administered the same dose. CONCLU-
SIONS: The effects of Pioglitazone on the cardiovascular risk
factors are almost the same in different ethnic groups, whereas
those of Rosiglitazone varies with ethnicity. In this regards, well-
designed head-to-head comparative trials as well as long-term
cardiovascular outcome studies should be conducted in order to
accurately determine the various effects of the two thiazolidinedi-
ones on different ethnic groups.
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OBJECTIVES: The objective was to estimate the long-term clini-
cal outcomes in pharmaceutical treatment naïve type 2 diabetes
patients when initiated with biphasic insulin aspart (BIAsp) in a
secondary care setting in urban China. METHODS: A validated
computer simulation model of diabetes (the CORE Diabetes
Model) was used to make long-term projections of clinical out-
comes based on patient characteristics (mean age 49.7 years, time
since diagnosis 1.61 years, HbA1c 9.86%, BMI 24.62 kg.m-2)
and treatment effects of BIAsp (HbA1c improvement of 3.27
percentage points, an increase in hypoglycaemic events of 2.4 per
patient-year). All background and treatment data were obtained
from the Chinese part of the IMPROVE study (n = 7012). Treat-
ment management practices were taken from Chinese urban
hospitals. RESULTS: Superior glycemic control with BIAsp led to
a delay in the onset of diabetes-related complications by 0.31
years (1.16 vs 0.85), e.g. the delay of onset to neuropathy, myo-
cardial infarction and stroke were 1.09, 0.55, and 0.41 years,
respectively. The cumulative incidence of complications was pro-
jected to decrease with BIAsp in the majority of parameters
studied e.g. the incidence of neuropathy was decreased by 9.3%.
Life expectancy increased from 13.62 to 14.05 years. Quality-
adjusted life years (QALYs) (mean  sd) increased by 0.772
(9.01  0.171 vs 8.24  0.146). CONCLUSIONS: The long
term health outcome projections based on surrogate endpoints
reported in the Chinese cohort of the IMPROVE study, indicate
that initiating treatment with BIAsp in treatment naïve (including
OAD naïve) type 2 diabetes patients will improve life expectancy
and quality-adjusted life years, delay the onset of diabetes related
complications, and reduce their cumulative incidence over
patient lifetimes.
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OBJECTIVES: To assess diabetes disease burden and associated
treatment patterns among six European nations. METHODS: A
large multi-country online cross-sectional survey of approxi-
mately 175,000 adults was conducted in 2007 in France,
Germany, Italy, Spain, UK and the The Netherlands by TNS
Healthcare. The survey enabled TNS to build an epidemiological
database based on its proprietary European Healthcare Panel
(EHP) of consumers in these 6 countries. The data is representa-
tive of population gender and age (18–24, 25–34, 35–44, 45–54,
55–64, 65–69 yrs) strata in respective countries, ensured by sam-
pling and intensive panel management. The survey collected
information on select health conditions (incl. diabetes; in the past
12-months) and health care-utilization. RESULTS: Diabetes
disease prevalence varied widely between the 6 nations, as
follows (All pts, Males/Females, proportion type 1/type
2/Gestational/Unknown): Italy: 4%, 5%/3%, 28%/61%/3%/
8%; France: 5%, 5%/4%, 21%/63%/4%/12%; Spain: 5%,
6%/4%, 18%/66%/3%/13%; The Netherlands: 5%, 6%/5%,
13%/84%/1%/1%; Germany: 6%, 6%/5%, 14%/81%/1%/4%;
Abstracts A497
